Welcome to our dedicated page for SERNOVA news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on SERNOVA stock.
Sernova Corp. is a clinical-stage biotechnology company focused on developing therapeutic cell technologies for chronic diseases like insulin-dependent diabetes, thyroid disease, and hemophilia A. The company's lead asset, the Cell Pouch System, is an implantable medical device that creates a natural vascularized tissue environment for long-term survival of therapeutic cells. Sernova's technology aims to provide a 'functional cure' for diabetes and other chronic conditions by releasing essential factors to address deficiencies in patients' bodies. The company is also working on shielding therapeutic cells from immune system attacks and developing an off-the-shelf iPSC-based islet replacement therapy in partnership with Evotec. In addition, Sernova is progressing programs for hypothyroid disease and hemophilia A using its Cell Pouch System.
Sernova Corp. (TSX:SVA; OTCQB:SEOVF) announced promising preclinical results for its partnership with Evotec SE, focusing on iPSC-derived islet-like clusters (ILCs) for treating Type 1 Diabetes (T1D). Key findings showcased that Evotec's scalable GMP manufacturing process yields ILCs with high insulin-producing beta cell content and successful glycemic control in diabetic mouse models. Results indicated that ILCs implanted in Sernova's Cell Pouch demonstrated blood sugar normalization akin to human islets over a 320-day study. The companies are on track for an IND filing and Phase 1/2 clinical trial in 2024, aiming to offer a commercially viable off-the-shelf treatment for diabetes. The preclinical data was presented at the IPITA/HSCI/JDRF Summit in April 2023, underscoring the significant potential for a 'functional cure' for T1D.
Sernova Corp. (OTCQB:SEOVF), a leader in cell therapeutics, announces that CEO Dr. Philip Toleikis will present at the Cell & Gene Meeting on the Med in Barcelona, Spain, from April 12-14, 2023. The presentation, titled Navigating CGTx Development in 2023, is scheduled for April 12, 2023, from 4:45 PM to 5:30 PM CET at the BioCentriq Ballroom. Virtual attendance will be available, providing access to Sernova’s presentation and all on-demand conference sessions. Credentialed investors can attend for free by contacting Laura Stringham. Sernova focuses on developing cell therapies for chronic diseases, including its Cell Pouch System aimed at providing a functional cure for insulin-dependent diabetes. This system fosters the long-term survival of therapeutic cells, promising advancements in treating chronic conditions.
Sernova Corp. addressed misleading claims from dissident shareholders regarding its board renewal process and proxy battle. The company asserts that its management has positioned Sernova for value creation, evidenced by a 17% year-to-date share price increase, outperforming the 8% decline in the Nasdaq XBI biotech index. Despite challenges in the biotech sector, Sernova's clinical trial advancements and technology partnerships, specifically with Evotec SE, are poised to enhance shareholder value. Upcoming milestones include clinical trial updates for type-1 diabetes and a hypothyroid disease program. Sernova ended Q1 2023 with cash resources of $45.6 million, providing a solid financial foundation for ongoing and future projects.
FAQ
What is the current stock price of SERNOVA (SEOVF)?
What is the market cap of SERNOVA (SEOVF)?
What is Sernova Corp. focused on developing?
What is the Cell Pouch System developed by Sernova Corp.?
What is the goal of Sernova's technology in addressing chronic diseases?
What partnership has Sernova entered into for developing an islet replacement therapy?
What additional programs is Sernova working on using the Cell Pouch System?
How does Sernova plan to shield therapeutic cells from immune system attacks?
What is Sernova's approach to providing potentially unlimited insulin-producing cells for diabetes treatment?
What is the status of Sernova's ongoing clinical study for diabetes treatment?
Who is the research collaboration partner of Sernova in the field of Hemophilia A?
Where can one find more information about Sernova Corp.?
What recent achievement has Sernova Corp. announced related to the Cell Pouch System?
